295 related articles for article (PubMed ID: 36198555)
1. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
Kagoya Y
Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
[TBL] [Abstract][Full Text] [Related]
2. Cytokine signaling in chimeric antigen receptor T-cell therapy.
Kagoya Y
Int Immunol; 2024 Feb; 36(2):49-56. PubMed ID: 37591521
[TBL] [Abstract][Full Text] [Related]
3. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
Kim SJ; Yoon SE; Kim WS
Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
[TBL] [Abstract][Full Text] [Related]
4. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
[TBL] [Abstract][Full Text] [Related]
5. Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients.
Gagelmann N; Ayuk FA; Klyuchnikov E; Wolschke C; Berger SC; Kröger N
Haematologica; 2023 Oct; 108(10):2799-2802. PubMed ID: 36815380
[No Abstract] [Full Text] [Related]
6. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Stem Cell Res Ther; 2021 Oct; 12(1):527. PubMed ID: 34620233
[TBL] [Abstract][Full Text] [Related]
7. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
8. Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Hoda D; Richards R; Faber EA; Deol A; Hunter BD; Weber E; DiFilippo H; Henderson-Clark T; Meaux L; Crivera C; Riccobono C; Garrett A; Jackson CC; Fowler J; Theocharous P; Stewart R; Lorden AL; Porter DL; Berger A
Future Oncol; 2022 Jun; 18(19):2415-2431. PubMed ID: 35583358
[TBL] [Abstract][Full Text] [Related]
9. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T-cells: Properties, production, and quality control.
Ramesh P; Hui HYL; Brownrigg LM; Fuller KA; Erber WN
Int J Lab Hematol; 2023 Aug; 45(4):425-435. PubMed ID: 37337970
[TBL] [Abstract][Full Text] [Related]
11. [Development of Novel Gene-Modified T-Cell Therapies(CAR-T, TCR-T)].
Kitano S
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1032-1037. PubMed ID: 38035829
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myeloma-A Call for Equal Opportunity.
Goldfinger M; Shah N; Cooper DL
JAMA Oncol; 2023 Mar; 9(3):297-298. PubMed ID: 36602789
[TBL] [Abstract][Full Text] [Related]
13. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
Hosen N
Rinsho Ketsueki; 2018; 59(10):2189-2194. PubMed ID: 30305525
[TBL] [Abstract][Full Text] [Related]
14. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation CAR T-cell Therapies.
Young RM; Engel NW; Uslu U; Wellhausen N; June CH
Cancer Discov; 2022 Jul; 12(7):1625-1633. PubMed ID: 35417527
[TBL] [Abstract][Full Text] [Related]
16. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Cohen AD
Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
[No Abstract] [Full Text] [Related]
17. The Future of Chimeric Antigen Receptor T Cell Therapy.
Smith EL
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1215-1219. PubMed ID: 37442674
[TBL] [Abstract][Full Text] [Related]
18. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight.
Wang B; Rajeeve S; Madduri D
Cancer J; 2021 May-Jun 01; 27(3):205-212. PubMed ID: 34549909
[TBL] [Abstract][Full Text] [Related]
20. The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies.
Nath K; Mailankody S; Usmani SZ
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1201-1214. PubMed ID: 37330347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
